Skip to main content
Notable Settlement
Healthcare
$556 Million

Kaiser Permanente — Medicare Advantage Diagnosis Fraud

Kaiser Permanente Affiliates Pay $556 Million for Medicare Advantage Fraud

By Angie KellyLast updated: January 23, 2025

Source: U.S. Department of Justice

TL;DR: Kaiser Permanente Affiliates Pay $556 Million for Medicare Advantage Fraud This case resulted in a $556 Million resolution and demonstrates the impact of whistleblower protections in recovering funds from fraud.

Summary

Kaiser Permanente affiliates agreed to pay $556 million to resolve False Claims Act allegations that they fraudulently increased Medicare Advantage reimbursements by submitting inflated claims with invalid diagnosis codes. DOJ alleged that from 2009 through 2018, Kaiser pressured physicians to add diagnoses after patient visits via "addenda" to medical records, thereby inflating the "risk scores" used to calculate Medicare Advantage payments. The settlement was one of the largest Medicare Advantage fraud recoveries in FCA history, and whistleblowers received $95 million for their role in bringing the case.

Our Take

Medicare Advantage fraud cases often center on "risk adjustment" gaming—the systematic addition of diagnosis codes that don't reflect genuine clinical findings. Insiders typically have access to the pressure points: addenda policies, physician pushback, compliance warnings that were overridden, and analytics showing diagnosis patterns that don't match clinical reality. If you've seen "chart review" programs that function as revenue optimization rather than accuracy improvement, preserve the training materials, the metrics used to evaluate success, and any communications showing leadership awareness of the gap between documentation and patient conditions.

Read the full article from the original source:

View Original Article

Opens in a new tab. Content from U.S. Department of Justice.

Notice

The summaries above are based on publicly available information released by the U.S. Department of Justice and are provided for informational purposes only. They do not constitute legal advice, investigative findings, or allegations by Disclosure Strategy. Our commentary reflects general, experience-based observations about how False Claims Act matters commonly arise and is not a statement about any party's liability.